Since several CDK4/CDK6 inhibitors have been also used in clinical trials in various types of cancers [39], it would be worth investigating the effectiveness of combinational therapies using BET bromodomain inhibitors as well as CDK6 inhibitors for SCLC patients. Here, CDK4 is linked to small cell lung carcinoma.